Surface Oncology, Inc. Common Stock
SURF
SURF was delisted on the 7th of September, 2023.
0 hedge funds and large institutions have $0 invested in Surface Oncology, Inc. Common Stock in 2023 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 61 closing their positions.
100% less funds holding
Funds holding: 61 → 0 (-61)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
100% less capital invested
Capital invested by funds: $16.9M → $0 (-$16.9M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 61
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$4.25M |
| 2 |
AVAI
Atlas Venture Associates IX
Boston,
Massachusetts
|
-$2.56M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$2.01M |
| 4 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
-$1.23M |
| 5 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$957K |
SURF Hedge Fund Activity: Q3 2023 in Review
0 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Surface Oncology, Inc. Common Stock (SURF) for Q3 2023, worth a combined $0 — down 100% from $16.9M a quarter earlier.
Sellers outnumbered buyers: 61 funds closed out of SURF and 0 opened new positions — a net loss of 61 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Armistice Capital, exiting entirely with an estimated $4.25M sold.
- 0 institutional investors held Surface Oncology, Inc. Common Stock (SURF) as of Q3 2023, down from 61 in Q2 2023.
- Funds reported $0 of Surface Oncology, Inc. Common Stock stock for Q3 2023, down 100% quarter-over-quarter.
- 0 funds opened new Surface Oncology, Inc. Common Stock positions in Q3 2023 and 61 closed out, a net change of -61 holders.
- The largest Surface Oncology, Inc. Common Stock seller in Q3 2023 was Armistice Capital, an estimated $4.25M sold.
Based on aggregated 13F filings for Q3 2023.